| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Wenying Yi, Shenglin She, Jie Zhang, Haibo Wu, Yingjun Zheng, Yuping Nin. Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital. Neuropsychiatric disease and treatment. vol 16. 2020-12-07. PMID:33262597. |
clozapine use in patients with early-stage schizophrenia in a chinese psychiatric hospital. |
2020-12-07 |
2023-08-13 |
Not clear |
| Wenying Yi, Shenglin She, Jie Zhang, Haibo Wu, Yingjun Zheng, Yuping Nin. Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital. Neuropsychiatric disease and treatment. vol 16. 2020-12-07. PMID:33262597. |
previous studies suggest that clozapine is commonly underutilized and that its initiation is delayed in patients with first-episode schizophrenia. |
2020-12-07 |
2023-08-13 |
Not clear |
| Wenying Yi, Shenglin She, Jie Zhang, Haibo Wu, Yingjun Zheng, Yuping Nin. Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital. Neuropsychiatric disease and treatment. vol 16. 2020-12-07. PMID:33262597. |
knowledge regarding clozapine use among chinese patients with early-stage schizophrenia is limited. |
2020-12-07 |
2023-08-13 |
Not clear |
| Wenying Yi, Shenglin She, Jie Zhang, Haibo Wu, Yingjun Zheng, Yuping Nin. Clozapine Use in Patients with Early-Stage Schizophrenia in a Chinese Psychiatric Hospital. Neuropsychiatric disease and treatment. vol 16. 2020-12-07. PMID:33262597. |
the aim of the present study was to investigate the point prevalence of and patterns and factors associated with clozapine use in patients with early-stage schizophrenia discharged from a psychiatric hospital in china. |
2020-12-07 |
2023-08-13 |
Not clear |
| Ana Miruna Dragoi, Ioana Radulescu, Bogdana Adriana Năsui, Anca Lucia Pop, Valentin Nicolae Varlas, Simona Trif. Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19. Brain sciences. vol 10. issue 11. 2020-12-01. PMID:33187329. |
clozapine (clz) use is precarious due to its neurological, cardiovascular, and hematological side effects; however, it is the gold standard in therapy-resistant schizophrenia (trs) in adults and is underused. |
2020-12-01 |
2023-08-13 |
Not clear |
| Jing Qiu, Hongxia Gong, Bixin Wang, Weiguo Gu, Lei Wang, Miaomiao Gu, Yuan Zhang, Xiangdong D. The use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia. Archives of osteoporosis. vol 15. issue 1. 2020-11-30. PMID:32601884. |
the use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia. |
2020-11-30 |
2023-08-13 |
Not clear |
| Katharina Robichon, Vimal Patel, Bronwen Connor, Anne Camille La Flamm. Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis. Journal of neuroinflammation. vol 17. issue 1. 2020-11-23. PMID:32050980. |
atypical antipsychotic agents, such as clozapine, are used to treat schizophrenia and other psychiatric disorders by a mechanism that is believed to involve modulating the immune system. |
2020-11-23 |
2023-08-13 |
Not clear |
| Parita Shah, Yusuke Iwata, Eric E Brown, Julia Kim, Marcos Sanches, Hiroyoshi Takeuchi, Shinichiro Nakajima, Margaret Hahn, Gary Remington, Philip Gerretsen, Ariel Graff-Guerrer. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. European archives of psychiatry and clinical neuroscience. vol 270. issue 1. 2020-11-06. PMID:31428862. |
clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. |
2020-11-06 |
2023-08-13 |
Not clear |
| Robert Løvsletten Smith, Kevin O'Connell, Lavinia Athanasiu, Srdjan Djurovic, Marianne Kristiansen Kringen, Ole A Andreassen, Espen Molde. Correction: Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. Translational psychiatry. vol 10. issue 1. 2020-11-05. PMID:33139722. |
correction: identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. |
2020-11-05 |
2023-08-13 |
Not clear |
| Yi-Hang Chiu, Chia-Yueh Hsu, Mong-Liang Lu, Chun-Hsin Che. Augmentation Strategies for Clozapine-Resistant Patients with Schizophrenia. Current pharmaceutical design. vol 26. issue 2. 2020-11-03. PMID:31924152. |
clozapine has been used in treatment-resistant patients with schizophrenia. |
2020-11-03 |
2023-08-13 |
Not clear |
| Yi-Hang Chiu, Chia-Yueh Hsu, Mong-Liang Lu, Chun-Hsin Che. Augmentation Strategies for Clozapine-Resistant Patients with Schizophrenia. Current pharmaceutical design. vol 26. issue 2. 2020-11-03. PMID:31924152. |
however, only 40% of patients with treatment-resistant schizophrenia have response to clozapine. |
2020-11-03 |
2023-08-13 |
Not clear |
| Imogen Stokes, Siân Lowri Griffiths, Rowena Jones, Linda Everard, Peter B Jones, David Fowler, Joanne Hodgekins, Tim Amos, Nick Freemantle, Vimal Sharma, Max Marshall, Swaran P Singh, Max Birchwood, Rachel Upthegrov. Prevalence of treatment resistance and clozapine use in early intervention services. BJPsych open. vol 6. issue 5. 2020-10-29. PMID:32938513. |
clozapine is the only evidence-based pharmacologic intervention available for people with treatment-resistant schizophrenia; current guidelines recommend commencement after two unsuccessful trials of standard antipsychotics. |
2020-10-29 |
2023-08-13 |
Not clear |
| Balwinder Singh, Andrew J Hughes, James L Roeri. Comfort Level and Barriers to the Appropriate Use of Clozapine: a Preliminary Survey of US Psychiatric Residents. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry. vol 44. issue 1. 2020-10-26. PMID:31713078. |
clozapine is the gold standard treatment for treatment-resistant schizophrenia. |
2020-10-26 |
2023-08-13 |
Not clear |
| A G Villasante-Tezanos, C Rohde, J Nielsen, J de Leo. Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. Acta psychiatrica Scandinavica. vol 142. issue 1. 2020-10-13. PMID:32415875. |
pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. |
2020-10-13 |
2023-08-13 |
Not clear |
| Juan Andrés Martínez-Andrés, Juan Antonio García-Carmon. Clozapine, a controversial gold standard antipsychotic for the 21st century: Switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. Schizophrenia research. vol 212. 2020-10-02. PMID:31421972. |
clozapine, a controversial gold standard antipsychotic for the 21st century: switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. |
2020-10-02 |
2023-08-13 |
Not clear |
| Patrick Davey, Siobhan Gee, Sukhi S Shergil. Inflammatory response to clozapine in the absence of myocarditis: case report. BJPsych open. vol 2. issue 3. 2020-10-01. PMID:27703781. |
a case is presented of a 25-year-old man with treatment-resistant paranoid schizophrenia whose only previous trial of clozapine had been stopped following a suspected clozapine-induced myocarditis. |
2020-10-01 |
2023-08-13 |
Not clear |
| Tongeji E Tungaraz. Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject. Therapeutic advances in psychopharmacology. vol 6. issue 5. 2020-10-01. PMID:27721972. |
it has been repeatedly shown that clozapine is more efficacious than other antipsychotics in the management of treatment-resistant schizophrenia. |
2020-10-01 |
2023-08-13 |
human |
| Tongeji E Tungaraz. Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject. Therapeutic advances in psychopharmacology. vol 6. issue 5. 2020-10-01. PMID:27721972. |
coordinated studies to examine these groups of patients may provide some insight, not only in the mechanism of clozapine-induced weight loss, but also in the better management of patients with treatment-resistant schizophrenia involving clozapine use. |
2020-10-01 |
2023-08-13 |
human |
| Asiel Yair Adan Sanchez, Jessica J Foster, Carla M Plymen, Sukhi Shergil. Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report. BJPsych open. vol 2. issue 6. 2020-10-01. PMID:28138403. |
clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report. |
2020-10-01 |
2023-08-13 |
Not clear |
| Satya K Trivedi, Ajish G Mangot, Siddhartha Sinh. Aripiprazole-induced priapism. Industrial psychiatry journal. vol 25. issue 1. 2020-10-01. PMID:28163420. |
polymorphism of alpha-2a adrenergic receptor gene in schizophrenia patients is known to be associated with sialorrhea while on clozapine treatment. |
2020-10-01 |
2023-08-13 |
Not clear |